Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Smoothened Homolog (Protein Gx or SMO) - Overview Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development AlfaSigma SpA F. Hoffmann-La Roche Ltd Genentech Inc Guangdong Zhongsheng Pharmaceutical Co Ltd IMPACT Therapeutics Inc Mayne Pharma Group Ltd PellePharm Inc Pfizer Inc Sun Pharma Advanced Research Company Ltd Smoothened Homolog (Protein Gx or SMO) - Drug Profiles glasdegib - Drug Profile Product Description Mechanism Of Action R&D Progress GSA-10 - Drug Profile Product Description Mechanism Of Action R&D Progress GT-1708 - Drug Profile Product Description Mechanism Of Action R&D Progress IMP-5471 - Drug Profile Product Description Mechanism Of Action R&D Progress itraconazole - Drug Profile Product Description Mechanism Of Action R&D Progress patidegib - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Antagonize SMO for Colon Cancer and Medulloblastoma - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecule to Target SMO and HDAC for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Antagonize SMO for Colorectal Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress sonidegib phosphate - Drug Profile Product Description Mechanism Of Action R&D Progress taladegib - Drug Profile Product Description Mechanism Of Action R&D Progress vismodegib - Drug Profile Product Description Mechanism Of Action R&D Progress ZSP-1602 - Drug Profile Product Description Mechanism Of Action R&D Progress Smoothened Homolog (Protein Gx or SMO) - Dormant Products Smoothened Homolog (Protein Gx or SMO) - Discontinued Products Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones Featured News & Press Releases Apr 01, 2019: PellePharm initiates pivotal phase 3 clinical trial of Patidegib topical gel in patients with gorlin syndrome Jan 30, 2019: Tolsura (suba-itraconazole) antifungal capsule now available in the United States Dec 18, 2018: Mayne Pharma announces US commercial rights for Suba-itraconazole in BCCNS Dec 12, 2018: Mayne pharma receives FDA approval of Tolsura (Suba-Itraconazole capsules) for the treatment of certain fungal infections Nov 23, 2018: FDA approves Pfizer’s Daurismo to treat acute myeloid leukaemia Oct 15, 2018: Pellepharm presents updated data from two phase 2 studies demonstrating the potential of Patidegib topical gel to treat basal cell carcinomas in patients with gorlin syndrome and in patients with non-gorlin sporadic bccs Oct 11, 2018: HedgePath Pharmaceuticals to present at the 2018 BioFlorida Annual Conference Oct 09, 2018: HedgePath Pharmaceuticals pathway for filing SUBA BCCNS NDA clarified in Meeting with FDA Aug 06, 2018: HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request Jun 27, 2018: U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway May 21, 2018: HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage May 16, 2018: PellePharm to present topical Patidegib and skin cancer epidemiological data at the 7th International Investigative Dermatology Meeting May 14, 2018: HedgePath Pharmaceuticals Announces Expanded Patent Coverage May 02, 2018: Mayne Pharma Announces FDA Acceptance of New Drug Application for Its Antifungal Suba-Itraconazole Capsule Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Indications, H1 2019 Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019 Number of Products under Development by Companies, H1 2019 Products under Development by Companies, H1 2019 Number of Products under Investigation by Universities/Institutes, H1 2019 Products under Investigation by Universities/Institutes, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Stage and Route of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019 Pipeline by AlfaSigma SpA, H1 2019 Pipeline by F. Hoffmann-La Roche Ltd, H1 2019 Pipeline by Genentech Inc, H1 2019 Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019 Pipeline by IMPACT Therapeutics Inc, H1 2019 Pipeline by Mayne Pharma Group Ltd, H1 2019 Pipeline by PellePharm Inc, H1 2019 Pipeline by Pfizer Inc, H1 2019 Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2019 Dormant Products, H1 2019 Discontinued Products, H1 2019List of Figures Number of Products under Development by Stage of Development, H1 2019 Number of Products under Development by Therapy Areas, H1 2019 Number of Products under Development by Top 10 Indications, H1 2019 Number of Products by Stage and Mechanism of Actions, H1 2019 Number of Products by Routes of Administration, H1 2019 Number of Products by Stage and Routes of Administration, H1 2019 Number of Products by Stage and Molecule Type, H1 2019

AlfaSigma SpA F. Hoffmann-La Roche Ltd Genentech Inc Guangdong Zhongsheng Pharmaceutical Co Ltd IMPACT Therapeutics Inc Mayne Pharma Group Ltd PellePharm Inc Pfizer Inc Sun Pharma Advanced Research Company Ltd